104 related articles for article (PubMed ID: 22043042)
1. The value of genomic analysis of breast cancer in drug development.
Szekely B; Pusztai L
J Natl Cancer Inst Monogr; 2011; 2011(43):60-2. PubMed ID: 22043042
[TBL] [Abstract][Full Text] [Related]
2. The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine.
Foekens JA; Wang Y; Martens JW; Berns EM; Klijn JG
Drug Discov Today; 2008 Jun; 13(11-12):481-7. PubMed ID: 18549973
[TBL] [Abstract][Full Text] [Related]
3. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
4. Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer.
Nagasaki K; Miki Y
Breast Cancer; 2008; 15(2):117-20. PubMed ID: 18274834
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibitors in breast cancer.
Telli ML; Ford JM
Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
[TBL] [Abstract][Full Text] [Related]
6. [Chemotherapy for breast cancer].
Nakayama T; Noguchi S
Gan To Kagaku Ryoho; 2011 Dec; 38(13):2569-73. PubMed ID: 22319837
[No Abstract] [Full Text] [Related]
7. New therapeutic approaches in breast cancer.
Davies E; Hiscox S
Maturitas; 2011 Feb; 68(2):121-8. PubMed ID: 21144683
[TBL] [Abstract][Full Text] [Related]
8. Advancing cancer drug discovery towards more agile development of targeted combination therapies.
Carragher NO; Unciti-Broceta A; Cameron DA
Future Med Chem; 2012 Jan; 4(1):87-105. PubMed ID: 22168166
[TBL] [Abstract][Full Text] [Related]
9. New developments in metastatic breast cancer: general discussion.
Vahdat LT; Rugo HS; Perez EA
Clin Adv Hematol Oncol; 2013; 11(10 Suppl 16):16-7. PubMed ID: 24765684
[No Abstract] [Full Text] [Related]
10. Aromatase inhibitors and breast cancer.
Miller WR
Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
[TBL] [Abstract][Full Text] [Related]
11. Genomic medicine. Gene expression tests foretell breast cancer's future.
Garber K
Science; 2004 Mar; 303(5665):1754-5. PubMed ID: 15031473
[No Abstract] [Full Text] [Related]
12. The effect of genetic variability on drug response in conventional breast cancer treatment.
Wiechec E; Hansen LL
Eur J Pharmacol; 2009 Dec; 625(1-3):122-30. PubMed ID: 19836373
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant breast cancer therapy: current status and future strategies--growth kinetics and the improved drug therapy of breast cancer.
Norton L
Semin Oncol; 1999 Feb; 26(1 Suppl 3):1-4. PubMed ID: 10203263
[TBL] [Abstract][Full Text] [Related]
14. [Proteomics and breast cancer: new perspectives and limitations].
Hondermarck H
Pathol Biol (Paris); 2006 May; 54(4):194-8. PubMed ID: 16632259
[TBL] [Abstract][Full Text] [Related]
15. Gene expression predictors in breast cancer: current status, limitations and perspectives.
Desmedt C; Ruíz-García E; André F
Eur J Cancer; 2008 Dec; 44(18):2714-20. PubMed ID: 18977656
[TBL] [Abstract][Full Text] [Related]
16. [Front-line drug discovery system for cancer].
Mizukami T
Gan To Kagaku Ryoho; 2008 Dec; 35(13):2293-300. PubMed ID: 19098393
[TBL] [Abstract][Full Text] [Related]
17. Overcoming drug resistance in patients with metastatic breast cancer.
Wong ST; Goodin S
Pharmacotherapy; 2009 Aug; 29(8):954-65. PubMed ID: 19637949
[TBL] [Abstract][Full Text] [Related]
18. What can be expected from the next generation of adjuvant breast cancer treatment?
Piccart-Gebhart M
Semin Oncol; 1999 Feb; 26(1 Suppl 3):22-5. PubMed ID: 10203267
[TBL] [Abstract][Full Text] [Related]
19. New directions for breast cancer therapeutic research.
Friedman MA
Hematol Oncol Clin North Am; 1994 Feb; 8(1):113-9. PubMed ID: 8150774
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer gene microarrays pass muster.
Twombly R
J Natl Cancer Inst; 2006 Oct; 98(20):1438-40. PubMed ID: 17047189
[No Abstract] [Full Text] [Related]
[Next] [New Search]
